This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05302/identifier/pubchem-compound/
n10http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB05302/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05302/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05302
rdf:type
n3:Drug
n3:description
Naltrexone depot produced statistically significant blockade of opiate effects for six weeks as measured by subjective rating scales and measurement of pupil size.
n3:generalReferences
# Modesto-Lowe V: Naltrexone depot (DrugAbuse Sciences). IDrugs. 2002 Aug;5(8):835-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12802700
n3:group
investigational
n3:indication
Investigated for use/treatment in alcohol dependence.
owl:sameAs
n10:DB05302
dcterms:title
naltrexone depot
adms:identifier
n6:4588651 n7:DB05302 n8:5485201
n3:mechanismOfAction
Naltrexone depot blocks the effects of hydromorphone, an opiate similar in effects to heroin.
n3:IUPAC-Name
n4:271B40BE-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B40C4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B40C3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B40C0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B40C1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B40C2-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B40BD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B40CA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B40CB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B40C5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B40C6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B40C8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B40C7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B40C9-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B40D0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B40D2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B40D3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B40CF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B40CE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B40D1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B40BF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B40CC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B40CD-363D-11E5-9242-09173F13E4C5